Sponsor

SynDevRx, Inc.

Clinical research sponsor

Published trials3

Recruiting shown2

Roles2

SourceClinicalTrials.gov

Clinical trials

3 shown

Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast CancerNCT05455619 · lead sponsor · 2022-08-26

RECRUITING

A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid TumorsNCT02743637 · lead sponsor · 2016-02-01

COMPLETED

A Study of SDX-7320 in Combination With Eribulin for People With Breast CancerNCT05570253 · collaborator · 2022-10-03

RECRUITING

Sponsor roles

lead sponsor2

collaborator1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.